New weekly shot could replace IV drips for nerve disease
NCT ID NCT07540221
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tests whether a weekly under-the-skin antibody treatment (XEMBIFY) provides similar blood levels as a standard IV infusion (Gamunex-C) given every 3 weeks in people with CIDP, a chronic nerve disorder. About 40 adults who are stable on IVIG will first receive Gamunex-C for 19 weeks, then switch to XEMBIFY for 16 weeks. The goal is to see if the weekly shot can match the IV treatment in maintaining antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Immune globulin (antibodies) given as XEMBIFY under the skin or Gamunex-C into a vein
- What this could lead to
- If successful, this could show that a weekly under-skin shot works as well as a once-every-3-weeks IV infusion for managing CIDP, offering more convenience.
- What could go wrong
- This is a small, early-phase study focused on drug levels, not on whether symptoms improve. It may not prove that XEMBIFY controls CIDP long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIDP (CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GC2402 Study Site 103
RECRUITINGPort Charlotte, Florida, 33952, United States
-
GC2402 Study Site 104
RECRUITINGRancho Mirage, California, 92270, United States
-
GC2402 Study Site 105
RECRUITINGMiami, Florida, 33067, United States
-
GC2402 Study Site 106
RECRUITINGSherman, Texas, 75092, United States
-
GC2402 Study Site 109
RECRUITINGCoral Springs, Florida, 33155, United States
-
GC2402 Study Site 110
RECRUITINGNew York, New York, 10003, United States
-
GC2402 Study Site 111
RECRUITINGCordova, Tennessee, 38018, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.